Related Experiment Video
Updated: Jul 4, 2025

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
RING finger E3 ligase, RNF138 inhibits osteoblast differentiation by negatively regulating Runx2 protein turnover
Vishal Upadhyay1,2, Anil Kumar Singh1,2, Shivani Sharma2,3
1Division of Cancer Biology, CSIR-Central Drug Research Institute, Lucknow, Utter Pradesh, India.
Abstract:
A few ubiquitin ligases have been shown to target Runx2, the key osteogenic transcription factor and thereby regulate bone formation. The regulation of Runx2 expression and function are controlled both at the transcriptional and posttranslational levels. Really interesting new gene (RING) finger ubiquitin ligases of which RNF138 is a member are important players in the ubiquitin-proteasome system, contributing to the regulation of protein turnover and cellular processes. Here, we demonstrated that RNF138 negatively correlated with Runx2 protein levels in osteopenic ovariectomized rats which implied its role in bone loss. Accordingly, RNF138 overexpression potently inhibited osteoblast differentiation of mesenchyme-like C3H10T1/2 as well primary rat calvarial osteoblast (RCO) cells in vitro, whereas overexpression of catalytically inactive mutant RNF138Δ18-58 (lacks RING finger domain) had mild to no effect. Contrarily, RNF138 depletion copiously enhanced endogenous Runx2 levels and augmented osteogenic differentiation of C3H10T1/2 as well as RCOs. Mechanistically, RNF138 physically associates within multiple regions of Runx2 and ubiquitinates it leading to its reduced protein stability in a proteasome-dependent manner. Moreover, catalytically active RNF138 destabilized Runx2 which resulted in inhibition of its transactivation potential and physiological function of promoting osteoblast differentiation leading to bone loss. These findings underscore the functional involvement of RNF138 in bone formation which is primarily achieved through its modulation of Runx2 by stimulating ubiquitin-mediated proteasomal degradation. Thus, our findings indicate that RNF138 could be a promising novel target for therapeutic intervention in postmenopausal osteoporosis.
Insights
RNF138 ubiquitin ligase targets Runx2, a key bone formation factor. Inhibiting RNF138 enhances Runx2 and bone growth, suggesting RNF138 as a therapeutic target for osteoporosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Bone Biology
Background:
- Runx2 is a critical transcription factor for bone formation, regulated at multiple levels.
- Ubiquitin ligases play roles in protein turnover and cellular processes via the ubiquitin-proteasome system.
- RNF138, a Really Interesting New Gene (RING) finger ubiquitin ligase, is implicated in regulating protein stability.
Purpose of the Study:
- To investigate the role of RNF138 in regulating Runx2 protein levels and osteoblast differentiation.
- To explore the potential of RNF138 as a therapeutic target for osteoporosis.
Main Methods:
- Correlation analysis of RNF138 and Runx2 protein levels in osteopenic rats.
- In vitro studies using C3H10T1/2 and primary rat calvarial osteoblast (RCO) cells to assess the effects of RNF138 overexpression and depletion on osteoblast differentiation.
- Investigation of the mechanism of Runx2 regulation by RNF138, including physical association, ubiquitination, and proteasomal degradation.
Main Results:
- RNF138 negatively correlated with Runx2 protein levels in osteopenic rats, suggesting a role in bone loss.
- RNF138 overexpression inhibited osteoblast differentiation, while RNF138 depletion enhanced it by increasing Runx2 levels.
- RNF138 directly ubiquitinates Runx2, leading to its proteasomal degradation and reduced protein stability, thereby inhibiting osteoblast differentiation and function.
Conclusions:
- RNF138 negatively regulates bone formation by promoting Runx2 degradation through the ubiquitin-proteasome pathway.
- RNF138 is a key modulator of Runx2 stability and osteogenic activity.
- RNF138 represents a potential therapeutic target for treating postmenopausal osteoporosis.
More Related Videos
Related Concept Videos
Negative Regulator Molecules
Osteoclasts in Bone Remodeling
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
TGF - β Signaling Pathway
Regulation of Angiogenesis and Blood Supply

